Nationwide Fund Advisors cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,131,483 shares of the biopharmaceutical company’s stock after selling 16,254 shares during the period. Nationwide Fund Advisors owned 0.09% of Gilead Sciences worth $80,086,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the last quarter. Penserra Capital Management LLC increased its position in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares in the last quarter. American Beacon Advisors Inc. bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $143,000. Sterling Investment Advisors Ltd. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $184,000. Finally, Washington Trust Bank increased its position in shares of Gilead Sciences by 24.8% during the second quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 550 shares in the last quarter. Institutional investors and hedge funds own 76.23% of the company’s stock.
A number of research firms have commented on GILD. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Thursday, August 31st. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target on the stock. in a research note on Monday, August 28th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a research note on Wednesday, September 6th. Finally, Oppenheimer assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $85.11.
In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the sale, the insider now owns 3,070,099 shares in the company, valued at $230,196,023.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 494,999 shares of company stock worth $37,404,139 in the last 90 days. 1.30% of the stock is currently owned by company insiders.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.57 on Thursday, hitting $72.72. 6,172,268 shares of the stock traded hands, compared to its average volume of 9,202,872. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The stock has a market cap of $95,736.46, a PE ratio of 7.65, a PEG ratio of -1.23 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the prior year, the company posted $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.86%. Gilead Sciences’s payout ratio is 23.69%.
COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Holdings Cut by Nationwide Fund Advisors” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2017/12/07/gilead-sciences-inc-gild-shares-sold-by-nationwide-fund-advisors-updated-updated.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.